Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026)

Climb Bio has reported Cash from Financing Activities for 6 years, with the latest figure at $5000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $5000.0; the trailing twelve-month figure through Mar 2026 stood at -$16000.0 (down 100.01% YoY), and the FY2025 full-year result was -$21000.0, down 100.02% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $5000.0, up from -$21000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $128.4 million in Q2 2024, with the low at -$21000.0 in Q4 2025.
• Historically, Cash from Financing Activities has averaged $13.2 million across 4 years, with a median of $32500.0 in 2023.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 534908.33% — and 2025, when it plunged 151.22%.
• Climb Bio's Cash from Financing Activities stood at $288000.0 in 2023, then slumped by 85.76% to $41000.0 in 2024, then sank by 151.22% to -$21000.0 in 2025, then surged by 123.81% to $5000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $5000.0 (Q1 2026), -$21000.0 (Q4 2025), and $41000.0 (Q4 2024), per Business Quant data.